March 16 (Reuters) - Lifecore Biomedical Inc LFCR.O:
LIFECORE BIOMEDICAL REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND TRANSITION PERIOD ENDED DECEMBER 31, 2025, AND PROVIDES CORPORATE UPDATE
LIFECORE BIOMEDICAL INC - EXPECTS 2026 REVENUE $120-$125 MILLION; ADJUSTED EBITDA $20.5-$25 MILLION
LIFECORE BIOMEDICAL INC - Q4 REVENUE $35.7 MILLION
LIFECORE BIOMEDICAL INC: Q4 EPS $-0.16